President Trump lays it out for big pharma: Drug prices must come down

dcnf-2-1Robert Donachie, DCNF

President Donald Trump met with executives from the pharmaceutical industry Tuesday morning at the White House to discuss ways to lower the exponentially increasing drug prices in the U.S.

Trump video message ss

Trump told the executives that “we have to lower drug prices,” increase research and development spending, and massively deregulate the pharmaceutical industry to lower barriers for entry of new drugs to the market.

Pricing of pharmaceuticals came into the public discourse when it was discovered in August that Mylan, the maker of the life-saving epinephrine injection device EpiPen, raised the price of the EpiPen 461 percent in under a decade.

The president met with the heads of Novartis AG, Merck & Co Inc, Johnson & Johnson, Celgene Corp, Eli Lilly & Co, and Amgen Inc. Also in attendance was the pharmaceutical industry’s lobbying group, the Pharmaceutical Research and Manufacturers of America.

Follow Robert on Twitter

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact [email protected]

DONATE TO BIZPAC REVIEW

Please help us! If you are fed up with letting radical big tech execs, phony fact-checkers, tyrannical liberals and a lying mainstream media have unprecedented power over your news please consider making a donation to BPR to help us fight them. Now is the time. Truth has never been more critical!

Success! Thank you for donating. Please share BPR content to help combat the lies.

Comment

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.

PLEASE JOIN OUR NEW COMMENT SYSTEM! We love hearing from our readers and invite you to join us for feedback and great conversation. If you've commented with us before, we'll need you to re-input your email address for this. The public will not see it and we do not share it.

Latest Articles